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Fig.2 Comparison of patients with 
undetectable VL depending on the 
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the HIV-1 group at W96 
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The divergent HIV-1 group O strains (HIV-1/O) are 
endemic in Cameroon and naturally resistant to NNRTI, 
largely used as first-line therapy in this country. 
Alternative therapeutic strategies are thus needed.  
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PATIENTS 
All consecutive HIV-1/O naïve patients with treatment initiation 
criteria were recruited from 2 hospitals Yaoundé and the Center 
Pasteur of Yaoundé (CPC), and included and followed up 
between June 2010 and July 2013. HIV-1/O patients were 
matched with HIV-1/M with a ratio of 1:2 on the basis of sex, 
age 18-40 and > 40 years, CD4 before initiation >350/mm3 - [350-
100]/mm3 - <100/mm3, Hb level <8g/l or >8g/l, and HBV status. 
HAART Treatment : HIV-1/M and HIV-1/O initiated the same 
treatment: AZT+3TC+LPV/r, or TDF+3TC+LPV/r for patients with 
anemia or HBV co-infection. 
METHODS 
• Primary end point: percentage of patients with an undetectable 
viral load (VL < 60 cp/mL) at W48.  
• Statistical analysis 
Primary endpoint analysis: Comparison of proportion of patients with 
undetectable VL according to the HIV-1 group at W96 with analyses on 
Intention to Treat Analysis/ITT (Death and Missing=Failure) and Per 
Protocol/PP. Secondary endpoint analysis :  Proportion of patients with 
a gain of more than 50% of CD4 at W12 and W48 according to the HIV-
1 group 
DynaM-O is a prospective open-label study.   
The main objective is to compare the immuno-virological 
response to HAART, including two NRTI and one PI in HIV-
1/O and HIV-1 group M (HIV-1/M) infected-naïve 
patients.  
Secondary objectives are to compare the kinetic of viral 
load responses, the CD4 restoration and the clinical 
events. 
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CONCLUSION 
47 Cameroonian patients HIV-1/O and 94 HIV-1/M were 
included; results were available for 128 patients (13 died or 
were lost-to follow-up; Fig.1). 
At baseline, VL was significantly lower (p< 0.0001) in HIV-
1/O with a median at 4.3 log cp/mL vs 5.1 log cp/mL in HIV-
1/M.  
Median CD4 counts were well balanced between the two 
groups (227 vs 215, in HIV-1/O and HIV-1/M respectively, 
p=0.68) 
At W96, 94.7 % [88.8 – 100] of HIV-1/O samples were < 60 
cp/mL vs 84.1 % [77.5% - 90.8%] of HIV-1/M in per protocol 
analysis (p=0.14); and no difference was observed at the 
threshold of 200 cp/mL (97% in both groups; Fig.2). 
Between treatment initiation and W96, CD4 cells count 
increase is significantly higher (p=0,04)  in the HIV-1/M group 
than in the HIV-1/O group (+2.0 CD4 per month for the HIV-
1/M, compare to HIV-1/O; Fig. 3). 
 
DynaM-O is the unique study analyzing the HAART responses in HIV-1/O infected patients compared to HIV-1/M patients. 
Data at W96 showed good efficacy of the regimens in both groups, but with a higher rate of achievement of the virological 
response in HIV-1/O infected patients. In contrast, the CD4 restoration was lower in HIV-1/O than that observed for HIV-1/M 
patients. These data indicate that group O infected patients should be successfully treated by treatment excluding NNRTI. 
Moreover, studying the mechanisms underlying these differences in response to HAART between these highly divergent HIV-1 
strains are of importance in our understanding of the HIV natural history. 
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Percent of patients with  
undetectable VL at W96 
[95% CI] 
P-value 
adjusted* 
  Per Protocol 
HIV-1/O (n=38) 94.7% [88.8%  ̶  100%] 0,14 
 HIV-1/M (n=81) 84.1% [77.5%  ̶  90.8%] 
  Intention To Treat 
HIV-1/O (n=47) 76.6% [64.4%  ̶  88.7%] 0,79 
 HIV-1/M (n=94) 73.4% [64.4%  ̶  82.3%] 
Fig.1 Flow Chart 
Fig.3 CD4 evolution from inclusion to W96 
